×
About 15,940 results

When Phase 3 Data Can't Guide Clinical Decision-Making in the Real-World--Lumpers vs Splitters
https://www.medscape.com/viewarticle/960555

Oct 14th, 2021 - In a perfect world, we would have phase 3 data to guide all of our clinical recommendations. But even if that were possible, phase 3 trials are not able to provide the full range of answers we need in a real-world setting. Do, for instance, the results from a trial of the most fit patients with great organ function apply to our older and somewhat frail patient with poor kidney function? In a wo...

Could Your Patient Benefit? New Trials in Lung Cancer
https://www.medscape.com/viewarticle/960851

Oct 14th, 2021 - Untreated PD-L1 non–small cell lung cancer (NSCLC). Patients with previously untreated, PD-L1-selected, locally advanced, unresectable, or metastatic NSCLC are sought for a phase 3 trial comparing pembrolizumab to the investigational immunotherapies ociperlimab (an anti-TIGIT antibody) and tislelizumab (an anti-PD-1 checkpoint inhibitor). Participants will be treated until death or progression ...

Case Report: Severe Hepatitis With Sotorasib After Immunotherapy
https://www.medscape.com/viewarticle/960882

Oct 14th, 2021 - A case report of life-threatening hepatitis in a lung cancer patient suggests caution in using second-line treatment with the newly approved targeted agent sotorasib (Lumakras) in patients who have previously been treated with checkpoint inhibitor (CPI) immunotherapy such as pembrolizumab (Keytruda). "Our case…represents an unexpected high-grade hepatic toxicity [with sotorasib]," say the autho...

FDA Approves Pembrolizumab Plus Chemo With or Without Bevacizumab for Frontline Cervical Cancer
https://www.onclive.com/view/fda-approves-pembrolizumab-plus-chemo-with-or-without-bevacizumab-for-frontline-cervical-cancer

Oct 13th, 2021 - The FDA has approved pembrolizumab (Keytruda) for use in combination with chemotherapy, with or without bevacizumab (Avastin), in patients with persistent, recurrent or metastatic cervical cancer whose tumors have a PD-L1 combined positive score (CPS) of 1 or higher, as determined by an FDA-approved test.1 The regulatory agency also granted regular approval to pembrolizumab as a monotherapy in...

How Breast Cancer Changed My Life...and Me
https://www.medscape.com/viewarticle/960536

Oct 8th, 2021 - Kristy Hammam Kristy Hammam retired in June 2021 as senior vice president and editor-in-chief for WebMD, where she directed editorial strategy and content creation. She began her career as a writer and copy editor at CNN. She has degrees in English and art history from Emory University. It's July 2019. I'm lying in the middle of the desert in southern Jordan, gazing up at the night sky. Wadi Ru...

Lenvatinib/Pembro Combo for Advanced Anaplastic Thyroid Cancer
https://www.medscape.com/viewarticle/960492

Oct 8th, 2021 - In patients with metastatic anaplastic thyroid cancer who have progressed on chemotherapy — who have a poor prognosis —a new combination of nonchemotherapy drugs shows promise. The combination of the multikinase inhibitor lenvatinib with the immunotherapy pembrolizumab has shown durable responses and encouraging survival rates in a small clinical trial. "Our results indicate that a combination ...

Dr. Reid on Remaining Challenges Regarding the Management of Immune-Related AEs
https://www.onclive.com/view/dr-reid-on-remaining-challenges-regarding-the-management-of-immune-related-aes

Oct 6th, 2021 - Pankti Reid, MD, MPH, rheumatologist, assistant professor ​of medicine, University of Chicago Medicine, discusses remaining challenges regarding the management of immune-related adverse effects (irAEs). Although the advent of multidisciplinary toxicity teams has facilitated efficient evaluation and management of multi-organ irAEs, challenges remain, Reid says. Moreover, optimization of diagn...

Dr. Atkins on the Impact of Georgetown Lombardi Cancer Center Consortium on Sarcoma Treatment
https://www.onclive.com/view/dr-atkins-on-the-impact-of-georgetown-lombardi-cancer-center-consortium-on-sarcoma-treatment

Oct 6th, 2021 - Michael B. Atkins, MD, the deputy director of Georgetown-Lombardi Comprehensive Cancer Center, as well as the Scholl Professor and vice chair of the Department of Medical Oncology at Georgetown University Medical Center, discusses the impact of the Georgetown Lombardi Cancer Center Consortium on the treatment of patients with sarcoma. In the case of a 19-year-old male with stage IV epithelioid...

Dr. Roland on the Safety of Neoadjuvant Checkpoint Blockade in Sarcoma
https://www.onclive.com/view/dr-roland-on-the-safety-of-neoadjuvant-checkpoint-blockade-in-sarcoma

Oct 6th, 2021 - Christina L. Roland, MD, MS, FACS, chief of Sarcoma Surgery and assistant professor in the Department of Surgical Oncology in the Division of Surgery; and associate medical director of the Sarcoma Center at The University of Texas MD Anderson Cancer Center, discusses the safety profile of neoadjuvant checkpoint blockade in patients with undifferentiated pleomorphic sarcoma (UPS) and dedifferent...

Dr. Schwartz on the Benefit of Dose Reduced Nivolumab/Ipilimumab in Metastatic Sarcomas
https://www.onclive.com/view/dr-schwartz-on-the-benefit-of-dose-reduced-nivolumab-ipilimumab-in-metastatic-sarcomas

Oct 6th, 2021 - Gary K. Schwartz, MD, a professor of medicine, chief of the Division of Hematology​/Oncology, and deputy director of Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the benefit of dose reducing ipilimumab (Yervoy) plus nivolumab (Opdivo) in metastatic sarcomas. Although there was no increase in responses in the ALLIANCE A091401 trial, there was a sug...

Dr. Trent on the Potential Role of Immunotherapy in GIST
https://www.onclive.com/view/dr-trent-on-the-potential-role-of-immunotherapy-in-gist

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the potential role of immunotherapy in gastrointestinal stromal tumors (GIST). Immunotherapy has demonstrated limited utility in patients with GIST, says Trent. A study from 2012 showed promising clinical outcomes with ...

Dr. Baskin on Treatment Considerations in Prostate Cancer
https://www.onclive.com/view/dr-baskin-on-treatment-considerations-in-prostate-cancer

Oct 6th, 2021 - Monica L. Baskin, PhD, professor, Division of Preventive Medicine, vice chair for culture and diversity, Department of Medicine, associate director, Community Outreach and Engagement, O’Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, discusses treatment considerations in prostate cancer. Treatment selection is based on a collaborative discussion with the patient a...

Dr. Sznol on Toxicities Associated With Immunotherapy in Melanoma
https://www.onclive.com/view/dr-sznol-on-toxicities-associated-with-immunotherapy-in-melanoma

Oct 6th, 2021 - Mario Sznol, MD, a professor of medicine and co-director of Yale SPORE in Skin Cancer at Yale Cancer Center, discusses toxicities associated with immunotherapy in patients with melanoma. The most common class of immunotherapy agent used in melanoma is anti–PD-1 inhibitors, according to Sznol. The immune adverse effects (AEs) seen with these agents and an earlier class of immune checkpoint inhi...

Dr. Tawbi on Future Research Efforts in Melanoma
https://www.onclive.com/view/dr-tawbi-on-future-research-efforts-in-melanoma

Oct 6th, 2021 - Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses future research efforts in melanoma. Although about 50% of patients with melanoma respond to available therapies, the rates of toxicities associated with single-agent and combination immunotherapy remain high, Tawbi says. As such, understanding how to better utilize immunotherapy in s...

Hunt for Reliable Biomarkers for Immunotherapy Continues in Melanoma
https://www.onclive.com/view/hunt-for-reliable-biomarkers-for-immunotherapy-continues-in-melanoma

Oct 6th, 2021 - Although immune checkpoint inhibitors have revolutionized the treatment of patients with melanoma, identifying reliable biomarkers of response to this approach has proven to be exceedingly challenging, according to Douglas B. Johnson, MD, MSCI. Obesity has been linked with improved responses to immune checkpoint inhibitors; however, the question regarding the association between body composi...

PVSRIPO Shows Promising Antitumor Activity in Refractory Melanoma
https://www.onclive.com/view/pvsripo-shows-promising-antitumor-activity-in-refractory-melanoma

Oct 6th, 2021 - Treatment with the novel intratumoral immuotherapy agent PVSRIPO resulted in an overall response rate (ORR) of 33% among all patients with anti–PD-1 refractory melanoma. Further, data from a phase 1 study demonstrated a 67% response among those who underwent a full course of treatment. However, investigators said it is too early to draw definitive conclusions based on these results because of t...

Research Reflections: Weber Relays Melanoma Updates From the 2021 ASCO Annual Meeting
https://www.onclive.com/view/research-reflections-weber-relays-melanoma-updates-from-the-2021-asco-annual-meeting

Oct 6th, 2021 - Welcome to OncLive On Air®! I’m your host today, Jessica Hergert. OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In tod...

FDA Approval Insights: Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF V600+ Advanced Melanoma
https://www.onclive.com/view/fda-approval-insights-atezolizumab-plus-cobimetinib-and-vemurafenib-in-braf-v600-advanced

Oct 6th, 2021 - Welcome to a very special edition of OncLive® On Air! I’m your host today, Caroline Seymour. OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important re...

Dr. Hamid on TMB as a Biomarker for Immunotherapy Response in Melanoma
https://www.onclive.com/view/dr-hamid-on-tmb-as-a-biomarker-for-immunotherapy-in-melanoma

Oct 6th, 2021 - Omid Hamid, MD, director of the Melanoma Center and Phase I Immuno-Oncology Program at The Angeles Clinic and Research Institute, discusses the utility of tumor mutational burden (TMB) as a biomarker for response to immunotherapy in patients with melanoma. TMB is not just for melanoma, says Hamid. By examining TMB, investigators have done a significant job in helping to understand which patien...

Novel Combo Elicits Clinical Responses in Patients With "Cold" Melanomas
https://www.onclive.com/view/novel-combo-elicits-clinical-responses-in-patients-with-cold-melanomas

Oct 6th, 2021 - Combining the PD-1 inhibitor pembrolizumab (Keytruda) with intratumoral plasmid interkeukin-12 (IL-12; tavokinogene telseplasmid; Tavo) electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma, according to results of a single-arm, phase 2 study (NCT02493361) published in Clinical Cancer Research.1 Notably, the combination demonstrated a 41% obje...